Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
14
14 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- EtoricoxibPhase 34 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- AR882Phase 33 trials
Arthrosi Therapeutics · Gout, Hyperuricemia, Gout Chronic
- DotinuradPhase 33 trials
Crystalys Therapeutics · Gout, Tophaceous Gout
- HRS-2129Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Acute Gouty Arthritis, Postoperative Analgesia, Postoperative Pain in Orthopaedics
- PlonmarlimabPhase 33 trials
TJ Biopharma Co., Ltd. · Acute Gouty Arthritis, Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytoses
- TigulixostatIBI128, LC350189Phase 33 trials
Innovent Biologics Technology Limited (Shanghai R&D Center) · Gout, Hyperuricemia, Gout Flare
- ABP-671Phase 32 trials
Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- Etoricoxib fixed doseEtoriPhase 32 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- HR091506Phase 31 trial
Jiangsu HengRui Medicine Co., Ltd. · Gout With Hyperuricemia in Adults
- ABP-745Phase 22 trials
Atom Therapeutics Co., Ltd · Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- BR2251Phase 21 trial
BioRay Pharmaceutical Co., Ltd. · Gout and Hyperuricemia
- PRX-115Phase 21 trial
Protalix · Gout
- SSGJ-613Phase 21 trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Gout Arthritis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.